ClinicalTrials.gg
CompletedNCT03912259Updated Dec 19, 2023Results posted

Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis

A Phase 3 interventional study of Dupilumab and Placebo in Atopic Dermatitis, sponsored by Sanofi. Completed at 27 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-19.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
20th of 50
165 · median 75
Started
2018
with 4 others
Phase 3
11 of 50
none open now
Registered
24th of 50
by date
Lead sponsor
10 of 50
Sanofi

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 20th largest by enrollment, is one of 5 that started in 2018, is one of 11 in phase 3, and was the 24th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the efficacy of dupilumab monotherapy compared to placebo treatment in adult participants with moderate-to-severe atopic dermatitis (AD).

Secondary Objectives:

  • To evaluate the safety of dupilumab monotherapy compared to placebo treatment in adult participants with moderate-to-severe AD.
  • To evaluate the effect of dupilumab on improving patient reported outcomes (PROs).
  • To evaluate dupilumab immunogenicity.
Read the detailed description

The maximum study duration was 33 weeks per participants, including a screening period of up to 5 weeks, a 16-week randomized treatment period, and a 12-week follow-up period.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 years or older.
  • AD (according to American Academy of Dermatology Consensus Criteria, 2014) that had been present for at least 3 years before the screening visit.
  • Eczema Area and Severity Index (EASI) score greater than or equal to (>=) 16 at the screening and baseline visits.
  • Investigator's Global Assessment (IGA) score >=3 (on the 0 to 4 IGA scale, in which 3 was moderate and 4 was severe) at the screening and baseline visits.
  • Participants with >=10 percent (%) body surface area (BSA) of AD involvement at the screening and baseline visits.
  • Baseline Pruritus Numerical Rating Scale (NRS) average score for maximum itch intensity >=4.
  • Documented recent history (within 6 months before the screening visit) of inadequate response to treatment with topical medications or for whom topical treatments were otherwise medically inadvisable (e.g., because of important side effects or safety risks).

Exclusion criteria

Exclusion criteria:

  • Had used any of the following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, was likely to require such treatment(s) during the first 4 weeks of study treatment:

    • /immunomodulating drugs (e.g., systemic , cyclosporine, mycophenolate-mofetil, interferon-gamma [IFN-γ], Janus kinase inhibitors, azathioprine, methotrexate);
    • Phototherapy for AD.
  • Treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) within 1 week before the baseline visit.
  • Treatment with systemic Traditional Chinese Medicine (TCM) within 4 weeks before the baseline visit or treatment with topical TCM within 1 week before the baseline visit.
  • Treatment with biologics as follows:

    • Any cell-depleting agents including but not limited to rituximab: within 6 months before the baseline visit, or until lymphocyte count returns to normal, whichever is longer;
    • Other biologics: within 5 half-lives (if known) or 16 weeks prior to baseline visit, whichever was longer.
  • Initiation of treatment of AD with prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products during the screening period (participants may continue using stable doses of such moisturizers if initiated before the screening visit).
  • Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks of the baseline visit.
  • Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.
  • Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit, or superficial skin infections within 1 week before the baseline visit. NOTE: participants may be rescreened after infection resolves.
  • Known or suspected history of immunosuppression, including history of invasive opportunistic infections (e.g., tuberculosis [TB], histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution: or unusually frequent, recurrent, or prolonged infections, per investigator judgment.
  • Active TB, latent untreated TB or a history of incompletely treated TB or non-tuberculous mycobacterial infection were excluded from the study unless that was well documented by a specialist that the participants had adequately treated and could then start treatment with a biologic agent, in the medical judgment of the Investigator and/or infectious disease specialist. TB testing would be performed according to local guidelines if required by regulatory authorities or ethics committees.

The above information was not intended to contain all considerations relevant to a participants potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
165 participants (actual)

Study arms

  • Placebo comparator
    Placebo Q2W

    Placebo matched to dupilumab 600 milligrams (mg) (loading dose), subcutaneously (SC) on Day 1 followed by placebo matched to dupilumab 300 mg once every 2 weeks (Q2W) for 16 weeks.

    Drug: Placebo · Drug: Emollient (moisturizer)

  • Experimental
    Dupilumab 300 mg Q2W

    Dupilumab at a loading dose of 600 mg, SC on Day 1 followed by 300 mg, Q2W for 16 weeks.

    Drug: Dupilumab · Drug: Emollient (moisturizer)

Interventions

  • Pharmaceutical form: solution, Route of administration: SC

    Also known as: Dupixent, SAR231893

  • DrugPlacebo

    Pharmaceutical form: solution, Route of administration: SC

  • DrugEmollient (moisturizer)

    Pharmaceutical form: cream, Route of administration: topical use

06

What researchers measure

Primary outcomes

  1. Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16

    The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Number of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Reduction in Score From Baseline) at Week 16

    EASI: Measure to assess severity and extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] and lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) and scored separately for each of 4 body regions (head, trunk, upper and lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.

    Time frame: Baseline, Week 16

  2. Number of Participants Who Achieved >=4 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 16

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

    Time frame: Baseline, Week 16

  3. Number of Participants Who Achieved >=3 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale Score at Week 16

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

    Time frame: Baseline, Week 16

  4. Percentage Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

    Time frame: Baseline, Week 16

  5. Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

    Time frame: Baseline, Week 16

  6. Percentage Change From Baseline to Week 16 in EASI Score

    EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3"(severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score ranges from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.

    Time frame: Baseline to Week 16

  7. Change From Baseline to Week 16 in Percent Body Surface Area (BSA) of AD Involvement

    BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and reported as a percentage of all major body sections combined. The reported percentage of BSA was combined percentage of all major body sections.

    Time frame: Baseline to Week 16

  8. Change From Baseline to Week 16 in Dermatology Life Quality Index (DLQI) Total Score

    The DLQI was a validated questionnaire used to measure the impact of AD disease symptoms and treatment on health-related quality of life (QOL). DLQI consisting of a set of 10 questions which assess QOL over the past week. Responses to each questions were assessed on a scale of 0 to 3, where 0 is "not at all" and 3 is "very much". Scores from all 10 questions added up to give total DLQI scores ranged from 0 (not at all) to 30 (very much), higher scores indicated more impact on quality of life.

    Time frame: Baseline to Week 16

  9. Change From Baseline to Week 16 in Patient Oriented Eczema Measure (POEM)

    The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a scale ranging from 0 to 4 (0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, 4 = all days). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). Higher scores indicated more severe disease and poor quality of life.

    Time frame: Baseline to Week 16

  10. Percentage Change From Baseline to Week 2 in Weekly Average of Peak Daily Pruritus NRS

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

    Time frame: Baseline to Week 2

  11. Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire (EQ-5D) Index Scores

    The EQ-5D is a standardized measure of health status which is consists of 2 parts; the descriptive system and the EQ visual analogue scale (EQVAS). The EQ-5D descriptive system includes 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: "no problem" (level 1), "some problems" (level 2), "extreme problems" (level 3). The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. The 5 dimensional 3-level systems was converted into single index utility score between 0 to 1 that quantify health status, where 0 represents "death" and 1 represents "perfect health".

    Time frame: Baseline to Week 16

  12. Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores

    The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analogue scale ranged from 0-100 where 100 indicated "best imaginable health state" and 0 indicated "worst imaginable health state", higher scores indicated better outcome.

    Time frame: Baseline to Week 16

  13. Absolute Change From Baseline to Week 16 in EQ-5D Index Scores

    The EQ-5D is a standardized measure of health status which consisted of 2 parts; the descriptive system and the EQVAS. The EQ-5D descriptive system includes 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: "no problem" (level 1), "some problems" (level 2), "extreme problems" (level 3). The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. The 5 dimensional 3-level systems was converted into single index utility score between 0 to 1 that quantify health status, where 0 represents "death" and 1 represents "perfect health".

    Time frame: Baseline to Week 16

  14. Absolute Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores

    The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analogue scale ranged from 0-100 where 100 indicated "best imaginable health state" and 0 indicated "worst imaginable health state", higher scores indicated better outcome.

    Time frame: Baseline to Week 16

  15. Number of Participants Who Achieve Reduction of IGA Score by >=2 From Baseline to Week 16

    The IGA is an assessment instrument used to rate the severity of AD globally, based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity. In this outcome measure, number of participants who achieved reduction from baseline of \>=2 points in IGA score at Week 16 were reported.

    Time frame: Baseline to Week 16

  16. Number of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16

    The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

  17. Absolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16

    EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD. Participants with missing EASI Score at each visit were imputed using MI (Multiple Imputation) method.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

  18. Percentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16

    EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16

  19. Number of Participants With EASI-50 (>=50% Improvement From Baseline) at Week 16

    EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.

    Time frame: Baseline, Week 16

  20. Number of Participants With EASI-90 (>=90% Improvement From Baseline) at Week 16

    EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.

    Time frame: Baseline, Week 16

  21. Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. Participants with missing Peak Daily Pruritus NRS Score at each visit were imputed using MI method.

    Time frame: From Baseline Through Week 16

  22. Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. Participants with missing peak NRS scores at each visit were imputed using MI method.

    Time frame: From Baseline Through Week 16

  23. Number of Participants Who Responded "Absence of Pruritus" or "Mild Pruritus" in the Pruritus Categorical Scale at Week 16

    The pruritus categorical scale was a 4-point scale used to assess symptoms of AD. The scale is rated as follows: 0: absence of pruritus; 1: mild pruritus (occasional slight itching/scratching); 2: moderate pruritus (constant or intermittent itching/scratching that does not disturb sleep) and 3: severe pruritus (bothersome itching/scratching that disturbs sleep), higher scores indicated worse outcome.

    Time frame: Week 16

  24. Number of Days of Sick Leave/Missed School Days

    Participants who were employed or enrolled in school for full time were asked to report the number of sick leave/missed school days since the last study assessment. Participants were counted as Full time if the participant checked "Full time" at all visits through 16-week treatment period and participants were counted as Part time if the participant checked at least one "Part time" during 16-week treatment period.

    Time frame: Week 16

  25. Percentage of Participants With at Least One Day Sick Leave/Missed School Days

    Participants who were employed or enrolled in school for full time were asked to report the number of sick leave/missed school days since the last study assessment. Participants were counted as Full time if the participant checked "Full time" at all visits through 16-week treatment period and participants were counted as Part time if the participant checked at least one "Part time" during 16-week treatment period.

    Time frame: Week 16

07

Results

Posted Apr 5, 2021

Participant flow

The study was conducted at 25 active centers in China between 19 Dec 2018 and 14 Feb 2020. A total of 165 participants were randomized and treated in the study.

Participant flow — Overall Study
MilestonePlacebo Q2WDupilumab 300 mg Q2W
Started8382
Completed6676
Not completed176
Withdrew: Adverse event (ae)24
Withdrew: Lack of efficacy41
Withdrew: Withdrawal by subject111

Outcome measures

PrimaryNumber of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16

The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.

Time frame:
Baseline, Week 16
Reported as:
Count of participants · Participants
Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16
ParticipantsPlacebo Q2WDupilumab 300 mg Q2W
Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16422
Statistical analysis
  • Placebo Q2W vs Dupilumab 300 mg Q2W · Cochran-Mantel-Haenszel · p = <.0001 (Threshold for significance at 0.05 level.) · Difference in percentage: 22.0 · 95% CI 11.37 to 32.65P-value was derived by the Cochran-Mantel-Haenszel test stratified by baseline disease severity (IGA=3 vs. IGA=4).
SecondaryNumber of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Reduction in Score From Baseline) at Week 16

EASI: Measure to assess severity and extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] and lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) and scored separately for each of 4 body regions (head, trunk, upper and lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.

Time frame:
Baseline, Week 16
Reported as:
Count of participants · Participants
Number of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Reduction in Score From Baseline) at Week 16
ParticipantsPlacebo Q2WDupilumab 300 mg Q2W
Number of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Reduction in Score From Baseline) at Week 161247
SecondaryNumber of Participants Who Achieved >=4 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 16

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

Time frame:
Baseline, Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Achieved >=4 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 16
ParticipantsPlacebo Q2WDupilumab 300 mg Q2W
Number of Participants Who Achieved >=4 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 16432
SecondaryNumber of Participants Who Achieved >=3 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale Score at Week 16

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

Time frame:
Baseline, Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Achieved >=3 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale Score at Week 16
ParticipantsPlacebo Q2WDupilumab 300 mg Q2W
Number of Participants Who Achieved >=3 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale Score at Week 16843
SecondaryPercentage Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percentage change
Percentage Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS
percentage changePlacebo Q2WDupilumab 300 mg Q2W
Percentage Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS-21.13 ± 3.610-48.59 ± 3.026
SecondaryChange From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS
units on a scalePlacebo Q2WDupilumab 300 mg Q2W
Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS-1.64 ± 0.272-3.84 ± 0.237
SecondaryPercentage Change From Baseline to Week 16 in EASI Score

EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3"(severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score ranges from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percentage change
Percentage Change From Baseline to Week 16 in EASI Score
percentage changePlacebo Q2WDupilumab 300 mg Q2W
Percentage Change From Baseline to Week 16 in EASI Score-39.44 ± 4.936-75.23 ± 3.879
SecondaryChange From Baseline to Week 16 in Percent Body Surface Area (BSA) of AD Involvement

BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and reported as a percentage of all major body sections combined. The reported percentage of BSA was combined percentage of all major body sections.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percentage of body surface area
Change From Baseline to Week 16 in Percent Body Surface Area (BSA) of AD Involvement
percentage of body surface areaPlacebo Q2WDupilumab 300 mg Q2W
Change From Baseline to Week 16 in Percent Body Surface Area (BSA) of AD Involvement-19.25 ± 2.557-37.76 ± 2.126
SecondaryChange From Baseline to Week 16 in Dermatology Life Quality Index (DLQI) Total Score

The DLQI was a validated questionnaire used to measure the impact of AD disease symptoms and treatment on health-related quality of life (QOL). DLQI consisting of a set of 10 questions which assess QOL over the past week. Responses to each questions were assessed on a scale of 0 to 3, where 0 is "not at all" and 3 is "very much". Scores from all 10 questions added up to give total DLQI scores ranged from 0 (not at all) to 30 (very much), higher scores indicated more impact on quality of life.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 16 in Dermatology Life Quality Index (DLQI) Total Score
units on a scalePlacebo Q2WDupilumab 300 mg Q2W
Change From Baseline to Week 16 in Dermatology Life Quality Index (DLQI) Total Score-5.06 ± 0.701-10.33 ± 0.625
SecondaryChange From Baseline to Week 16 in Patient Oriented Eczema Measure (POEM)

The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a scale ranging from 0 to 4 (0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, 4 = all days). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). Higher scores indicated more severe disease and poor quality of life.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 16 in Patient Oriented Eczema Measure (POEM)
units on a scalePlacebo Q2WDupilumab 300 mg Q2W
Change From Baseline to Week 16 in Patient Oriented Eczema Measure (POEM)-4.04 ± 0.788-12.89 ± 0.685
SecondaryPercentage Change From Baseline to Week 2 in Weekly Average of Peak Daily Pruritus NRS

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

Time frame:
Baseline to Week 2
Reported as:
Least squares mean · percentage change
Percentage Change From Baseline to Week 2 in Weekly Average of Peak Daily Pruritus NRS
percentage changePlacebo Q2WDupilumab 300 mg Q2W
Percentage Change From Baseline to Week 2 in Weekly Average of Peak Daily Pruritus NRS-4.75 ± 1.802-15.65 ± 1.818
SecondaryPercentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire (EQ-5D) Index Scores

The EQ-5D is a standardized measure of health status which is consists of 2 parts; the descriptive system and the EQ visual analogue scale (EQVAS). The EQ-5D descriptive system includes 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: "no problem" (level 1), "some problems" (level 2), "extreme problems" (level 3). The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. The 5 dimensional 3-level systems was converted into single index utility score between 0 to 1 that quantify health status, where 0 represents "death" and 1 represents "perfect health".

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percentage change
Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire (EQ-5D) Index Scores
percentage changePlacebo Q2WDupilumab 300 mg Q2W
Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire (EQ-5D) Index Scores2.92 ± 0.6928.00 ± 0.562
SecondaryPercentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores

The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analogue scale ranged from 0-100 where 100 indicated "best imaginable health state" and 0 indicated "worst imaginable health state", higher scores indicated better outcome.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percentage change
Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores
percentage changePlacebo Q2WDupilumab 300 mg Q2W
Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores60.19 ± 25.15490.32 ± 24.775
SecondaryAbsolute Change From Baseline to Week 16 in EQ-5D Index Scores

The EQ-5D is a standardized measure of health status which consisted of 2 parts; the descriptive system and the EQVAS. The EQ-5D descriptive system includes 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: "no problem" (level 1), "some problems" (level 2), "extreme problems" (level 3). The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. The 5 dimensional 3-level systems was converted into single index utility score between 0 to 1 that quantify health status, where 0 represents "death" and 1 represents "perfect health".

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline to Week 16 in EQ-5D Index Scores
units on a scalePlacebo Q2WDupilumab 300 mg Q2W
Absolute Change From Baseline to Week 16 in EQ-5D Index Scores0.02 ± 0.0060.06 ± 0.004
SecondaryAbsolute Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores

The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analogue scale ranged from 0-100 where 100 indicated "best imaginable health state" and 0 indicated "worst imaginable health state", higher scores indicated better outcome.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores
units on a scalePlacebo Q2WDupilumab 300 mg Q2W
Absolute Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores10.75 ± 2.68918.22 ± 2.243
SecondaryNumber of Participants Who Achieve Reduction of IGA Score by >=2 From Baseline to Week 16

The IGA is an assessment instrument used to rate the severity of AD globally, based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity. In this outcome measure, number of participants who achieved reduction from baseline of \>=2 points in IGA score at Week 16 were reported.

Time frame:
Baseline to Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Achieve Reduction of IGA Score by >=2 From Baseline to Week 16
ParticipantsPlacebo Q2WDupilumab 300 mg Q2W
Number of Participants Who Achieve Reduction of IGA Score by >=2 From Baseline to Week 16739
SecondaryNumber of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16

The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Reported as:
Count of participants · Participants
Number of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16
ParticipantsPlacebo Q2WDupilumab 300 mg Q2W
Week 202
Week 406
Week 809
Week 12416
Week 16422
SecondaryAbsolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16

EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD. Participants with missing EASI Score at each visit were imputed using MI (Multiple Imputation) method.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Reported as:
Mean · units on a scale
Absolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16
units on a scalePlacebo Q2WDupilumab 300 mg Q2W
Week 2-3.27 ± 7.974-12.48 ± 12.640
Week 4-6.45 ± 11.838-19.56 ± 13.687
Week 8-9.54 ± 10.947-22.45 ± 12.830
Week 12-11.23 ± 12.603-24.32 ± 14.191
Week 16-12.60 ± 12.484-25.87 ± 13.985
SecondaryPercentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16

EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Reported as:
Least squares mean · percentage change
Percentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16
percentage changePlacebo Q2WDupilumab 300 mg Q2W
Week 2-10.55 ± 2.977-35.69 ± 2.930
Week 4-19.28 ± 3.981-55.83 ± 3.684
Week 8-29.38 ± 4.147-65.84 ± 3.562
Week 12-35.26 ± 4.674-70.36 ± 4.047
Week 16-39.44 ± 4.936-75.23 ± 3.879
SecondaryNumber of Participants With EASI-50 (>=50% Improvement From Baseline) at Week 16

EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.

Time frame:
Baseline, Week 16
Reported as:
Count of participants · Participants
Number of Participants With EASI-50 (>=50% Improvement From Baseline) at Week 16
ParticipantsPlacebo Q2WDupilumab 300 mg Q2W
Number of Participants With EASI-50 (>=50% Improvement From Baseline) at Week 162458
SecondaryNumber of Participants With EASI-90 (>=90% Improvement From Baseline) at Week 16

EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.

Time frame:
Baseline, Week 16
Reported as:
Count of participants · Participants
Number of Participants With EASI-90 (>=90% Improvement From Baseline) at Week 16
ParticipantsPlacebo Q2WDupilumab 300 mg Q2W
Number of Participants With EASI-90 (>=90% Improvement From Baseline) at Week 16533
SecondaryAbsolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. Participants with missing Peak Daily Pruritus NRS Score at each visit were imputed using MI method.

Time frame:
From Baseline Through Week 16
Reported as:
Least squares mean · units on a scale
Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16
units on a scalePlacebo Q2WDupilumab 300 mg Q2W
Week 1-0.26 ± 0.106-0.63 ± 0.107
Week 2-0.38 ± 0.135-1.26 ± 0.136
Week 3-0.61 ± 0.153-1.90 ± 0.153
Week 4-0.69 ± 0.162-2.26 ± 0.159
Week 5-0.88 ± 0.191-2.61 ± 0.187
Week 6-0.96 ± 0.205-2.81 ± 0.201
Week 7-0.88 ± 0.214-3.14 ± 0.208
Week 8-1.04 ± 0.212-3.21 ± 0.205
Week 9-1.10 ± 0.218-3.29 ± 0.209
Week 10-1.12 ± 0.221-3.38 ± 0.210
Week 11-1.24 ± 0.231-3.52 ± 0.216
Week 12-1.34 ± 0.233-3.59 ± 0.213
Week 13-1.46 ± 0.246-3.65 ± 0.223
Week 14-1.53 ± 0.264-3.71 ± 0.241
Week 15-1.56 ± 0.262-3.81 ± 0.234
Week 16-1.64 ± 0.272-3.84 ± 0.237
SecondaryPercentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. Participants with missing peak NRS scores at each visit were imputed using MI method.

Time frame:
From Baseline Through Week 16
Reported as:
Least squares mean · percentage change
Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16
percentage changePlacebo Q2WDupilumab 300 mg Q2W
Week 1-2.95 ± 1.387-7.30 ± 1.405
Week 2-4.75 ± 1.802-15.65 ± 1.818
Week 3-7.92 ± 2.000-23.66 ± 1.988
Week 4-9.10 ± 2.118-28.17 ± 2.069
Week 5-11.56 ± 2.477-32.65 ± 2.410
Week 6-12.41 ± 2.623-35.01 ± 2.543
Week 7-11.37 ± 2.743-39.16 ± 2.642
Week 8-13.22 ± 2.710-40.36 ± 2.594
Week 9-14.03 ± 2.796-41.28 ± 2.655
Week 10-14.24 ± 2.857-42.51 ± 2.682
Week 11-15.72 ± 2.972-44.26 ± 2.746
Week 12-17.07 ± 3.048-45.37 ± 2.735
Week 13-18.80 ± 3.235-46.15 ± 2.845
Week 14-19.63 ± 3.501-47.04 ± 3.061
Week 15-19.96 ± 3.503-48.29 ± 3.009
Week 16-21.13 ± 3.610-48.59 ± 3.026
SecondaryNumber of Participants Who Responded "Absence of Pruritus" or "Mild Pruritus" in the Pruritus Categorical Scale at Week 16

The pruritus categorical scale was a 4-point scale used to assess symptoms of AD. The scale is rated as follows: 0: absence of pruritus; 1: mild pruritus (occasional slight itching/scratching); 2: moderate pruritus (constant or intermittent itching/scratching that does not disturb sleep) and 3: severe pruritus (bothersome itching/scratching that disturbs sleep), higher scores indicated worse outcome.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Responded "Absence of Pruritus" or "Mild Pruritus" in the Pruritus Categorical Scale at Week 16
ParticipantsPlacebo Q2WDupilumab 300 mg Q2W
Number of Participants Who Responded "Absence of Pruritus" or "Mild Pruritus" in the Pruritus Categorical Scale at Week 161249
SecondaryNumber of Days of Sick Leave/Missed School Days

Participants who were employed or enrolled in school for full time were asked to report the number of sick leave/missed school days since the last study assessment. Participants were counted as Full time if the participant checked "Full time" at all visits through 16-week treatment period and participants were counted as Part time if the participant checked at least one "Part time" during 16-week treatment period.

Time frame:
Week 16
Reported as:
Mean · Days
Number of Days of Sick Leave/Missed School Days
DaysPlacebo Q2WDupilumab 300 mg Q2W
Full time0.66 ± 2.0750.88 ± 3.468
Part time11.14 ± 20.9237.44 ± 9.202
SecondaryPercentage of Participants With at Least One Day Sick Leave/Missed School Days

Participants who were employed or enrolled in school for full time were asked to report the number of sick leave/missed school days since the last study assessment. Participants were counted as Full time if the participant checked "Full time" at all visits through 16-week treatment period and participants were counted as Part time if the participant checked at least one "Part time" during 16-week treatment period.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Day Sick Leave/Missed School Days
percentage of participantsPlacebo Q2WDupilumab 300 mg Q2W
Full time14.922.4
Part time72.775.0

Adverse events

Collected over All AEs were collected from signature of the informed consent form up to end of study regardless of seriousness or relationship to investigational product. Time frame for reporting of treatment emergent adverse events (TEAEs) was from first dose up to 28 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W0/83 (0%)4/83 (4.8%)57/83 (68.7%)
Dupilumab 300 mg Q2W0/82 (0%)1/82 (1.2%)56/82 (68.3%)
Most frequent serious events
Most frequent serious events
EventPlacebo Q2WDupilumab 300 mg Q2W
Lung AdenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/831/82
Anaphylactic ReactionImmune system disorders1/830/82
Connective Tissue DisorderMusculoskeletal and connective tissue disorders1/830/82
AsthmaRespiratory, thoracic and mediastinal disorders1/830/82
Dermatitis AtopicSkin and subcutaneous tissue disorders1/830/82
Most frequent other events
Most frequent other events
EventPlacebo Q2WDupilumab 300 mg Q2W
Dermatitis AtopicSkin and subcutaneous tissue disorders41/8336/82
Upper Respiratory Tract InfectionInfections and infestations10/8314/82
Protein Urine PresentInvestigations9/839/82
ConjunctivitisInfections and infestations4/838/82
Conjunctivitis AllergicEye disorders1/837/82
NasopharyngitisInfections and infestations2/836/82
FolliculitisInfections and infestations6/831/82
DiarrhoeaGastrointestinal disorders2/835/82
Blood Uric Acid IncreasedInvestigations5/831/82

Baseline characteristics

Analysis was performed on Intent-to-treat (ITT) population which consisted of all randomized participants.

Age, Continuous
Age, Continuous(years)Placebo Q2WDupilumab 300 mg Q2WTotal
Mean30.2 ± 12.4631.0 ± 10.4730.6 ± 11.49
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2WDupilumab 300 mg Q2WTotal
Female232447
Male6058118
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Q2WDupilumab 300 mg Q2WTotal
American Indian or Alaska Native000
Asian8382165
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Investigator's Global Assessment (IGA) Score
Investigator's Global Assessment (IGA) Score(Participants)Placebo Q2WDupilumab 300 mg Q2WTotal
IGA = 3373572
IGA = 4464793
08

Study locations

27 sites
  • Investigational Site Number 1560019
    Beijing, 100034, China
  • Investigational Site Number 1560001
    Beijing, 100044, China
  • Investigational Site Number 1560004
    Beijing, 100050, China
  • Investigational Site Number 1560003
    Beijing, 100191, China
  • Investigational Site Number 1560010
    Beijing, 100730, China
  • Investigational Site Number 1560021
    Changchun, 130021, China
  • Investigational Site Number 1560006
    Changsha, 410011, China
  • Investigational Site Number 1560017
    Chongqing, 400038, China
  • Investigational Site Number 1560026
    Hangzhou, 310006, China
  • Investigational Site Number 1560007
    Hangzhou, 310009, China
  • Investigational Site Number 1560013
    Jinan, 250013, China
  • Investigational Site Number 1560020
    Kunming, China
  • Investigational Site Number 1560030
    Lianyungang, 222002, China
  • Investigational Site Number 1560022
    Nanjing, 210042, China
  • Investigational Site Number 1560029
    Ningbo, China
  • Investigational Site Number 1560016
    Shanghai, 200040, China
  • Investigational Site Number 1560023
    Shanghai, 200092, China
  • Investigational Site Number 1560018
    Shanghai, 200433, China
  • Investigational Site Number 1560015
    Shanghai, 200443, China
  • Investigational Site Number 1560002
    Shenyang, 110001, China
  • Investigational Site Number 1560005
    Shenyang, 110001, China
  • Investigational Site Number 1560008
    Shenyang, 110004, China
  • Investigational Site Number 1560024
    Shenzhen, China
  • Investigational Site Number 1560027
    Tianjin, 300052, China
  • Investigational Site Number 1560028
    Wuxi, 214002, China
  • Investigational Site Number 1560012
    Xi'An, 710004, China
  • Investigational Site Number 1560025
    Yancheng, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Feb 2020, 13 months.

Results were first posted in Apr 2021, 1 year 1 month after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 13 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2018
First posted
Apr 11, 2019
StartActual
Dec 19, 2018
Primary completionActual
Feb 14, 2020
CompletionActual
Feb 14, 2020
Results first posted
Apr 5, 2021
Last update
Dec 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03912259
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 11, 2019
Start date
Dec 19, 2018
Primary completion
Feb 14, 2020
Completion
Feb 14, 2020
Results posted
Apr 5, 2021
Last update
Dec 19, 2023

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion